A detailed history of Russell Investments Group, Ltd. transactions in Legend Biotech Corp stock. As of the latest transaction made, Russell Investments Group, Ltd. holds 184,414 shares of LEGN stock, worth $7.41 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
184,414
Previous 183,741 0.37%
Holding current value
$7.41 Million
Previous $10.3 Million 20.75%
% of portfolio
0.01%
Previous 0.02%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 08, 2024

BUY
$39.5 - $57.22 $26,583 - $38,509
673 Added 0.37%
184,414 $8.17 Million
Q1 2024

May 08, 2024

BUY
$55.06 - $69.99 $4.58 Million - $5.82 Million
83,150 Added 82.66%
183,741 $10.3 Million
Q4 2023

Feb 05, 2024

SELL
$57.25 - $69.74 $542,329 - $660,647
-9,473 Reduced 8.61%
100,591 $6.05 Million
Q3 2023

Nov 13, 2023

BUY
$63.16 - $76.5 $1.63 Million - $1.98 Million
25,865 Added 30.72%
110,064 $7.39 Million
Q2 2023

Aug 10, 2023

BUY
$46.28 - $75.01 $1.47 Million - $2.38 Million
31,680 Added 60.32%
84,199 $5.81 Million
Q1 2023

May 09, 2023

SELL
$43.42 - $57.37 $115,193 - $152,202
-2,653 Reduced 4.81%
52,519 $2.53 Million
Q4 2022

Feb 08, 2023

BUY
$38.8 - $55.46 $702,978 - $1 Million
18,118 Added 48.9%
55,172 $2.75 Million
Q3 2022

Nov 04, 2022

BUY
$38.15 - $57.1 $416,750 - $623,760
10,924 Added 41.81%
37,054 $1.51 Million
Q2 2022

Jul 29, 2022

BUY
$33.54 - $55.0 $197,751 - $324,280
5,896 Added 29.14%
26,130 $1.44 Million
Q1 2022

May 05, 2022

BUY
$31.02 - $48.18 $627,658 - $974,874
20,234 New
20,234 $735,000
Q3 2020

Nov 09, 2020

SELL
$27.5 - $39.61 $44,000 - $63,376
-1,600 Closed
0 $0
Q2 2020

Aug 05, 2020

BUY
$36.1 - $42.56 $57,760 - $68,096
1,600 New
1,600 $65,000

Others Institutions Holding LEGN

About Legend Biotech Corp


  • Ticker LEGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 167,403,008
  • Market Cap $6.73B
  • Description
  • Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery and development of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multipl...
More about LEGN
Track This Portfolio

Track Russell Investments Group, Ltd. Portfolio

Follow Russell Investments Group, Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Russell Investments Group, Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Russell Investments Group, Ltd. with notifications on news.